Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

作者：Blum William^*; Klisovic Rebecca B; Becker Heiko; Yang Xiaoxia; Rozewski Darlene M; Phelps Mitch A; Garzon Ramiro; Walker Alison; Chandler Jason C; Whitman Susan P; Curfman John; Liu Shujun; Schaaf Larry; Mickle Jon; Kefauver Cheryl; Devine Steven M; Grever Michael R; Marcucci Guido; Byrd John C

来源：Journal of Clinical Oncology, 2010, 28(33): 4919-4925.

DOI：10.1200/JCO.2010.30.3339

Purpose Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia.
Patients and Methods Thirty-one adults with acute myeloid leukemia (AML) and four adults with acute lymphoblastic leukemia (ALL) were enrolled. Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data.
Results Patients had a median age of 63 years (range, 22 to 79 years) and a median of two prior therapies (range, one to four therapies). The DLT was fatigue; 50 mg/d was the MTD. Infectious complications were frequent. Plasma lenalidomide concentration increased proportionally with dose. In AML, five (16%) of 31 patients achieved complete remission (CR); three of three patients with cytogenetic abnormalities achieved cytogenetic CR (none with deletion 5q). Response duration ranged from 5.6 to 14 months. All responses occurred in AML with low presenting WBC count. No patient with ALL responded. Two of four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after development of cutaneous graft-versus-host disease, without donor leukocyte infusion.
Conclusion Lenalidomide was safely escalated to 50 mg daily for 21 days, every 4 weeks, and was active with relatively low toxicity in patients with relapsed/refractory AML. Remissions achieved after transplantation suggest a possible immunomodulatory effect of lenalidomide, and results provide enthusiasm for further studies in AML, either alone or in combination with conventional agents or other immunotherapies. J Clin Oncol 28:4919-4925.

• 出版日期2010-11-20